Company Description
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD).
The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
| Country | United States |
| Founded | 1994 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,051 |
| CEO | Mark Crossley |
Contact Details
Address: 10710 Midlothian Turnpike, Suite 125 North Chesterfield, Virginia 23235 United States | |
| Phone | 804 379 1090 |
| Website | indivior.com |
Stock Details
| Ticker Symbol | INDV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001625297 |
| ISIN Number | GB00BN4HT335 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mark Crossley | Chief Executive Officer and Executive Director |
| Ryan Preblick | Chief Financial Officer |
| Vishal Kalia | Chief Strategy and Operating Officer |
| Dr. Christian Heidbreder | Chief Scientific Officer |
| Jason Thompson | Vice President of Investor Relations |
| Cynthia Cetani | Chief Integrity and Compliance Officer |
| Jeffrey W. Burris J.D. | Chief Legal Officer |
| Angela Colon-Mahoney M.S. | Chief Human Resources Officer |
| Richard Simkin | Chief Commercial Officer |
| Hillel West | Chief Manufacturing and Supply Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | 8-K | Current Report |
| Mar 20, 2025 | ARS | Filing |
| Mar 18, 2025 | SCHEDULE 13G | Filing |
| Mar 4, 2025 | SCHEDULE 13D/A | Filing |
| Mar 4, 2025 | SCHEDULE 13D/A | Filing |
| Mar 4, 2025 | 8-K | Current Report |
| Mar 3, 2025 | 10-K | Annual Report |
| Mar 3, 2025 | 6-K | Report of foreign issuer |
| Feb 28, 2025 | 6-K | Report of foreign issuer |
| Feb 28, 2025 | 6-K | Report of foreign issuer |